Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)

PHASE3CompletedINTERVENTIONAL
Enrollment

695

Participants

Timeline

Start Date

September 7, 2017

Primary Completion Date

January 30, 2023

Study Completion Date

January 30, 2023

Conditions
Asthma
Interventions
BIOLOGICAL

Benralizumab

Benralizumab subcutaneously on study week 0 until study week 40 inclusive.

BIOLOGICAL

Placebo

Placebo subcutaneously on study week 0 until study week 40 inclusive.

Trial Locations (79)

100

Research Site, Taipei

112

Research Site, Taipei

114

Research Site, Taipei

333

Research Site, Taoyuan

1000

Research Site, Manila

5000

Research Site, Iloilo City

10050

Research Site, Hohhot

11765

Research Site, Uijeongbu-si

13620

Research Site, Seongnam-si

14010

Research Site, Baotou

14584

Research Site, Bucheon-si

16499

Research Site, Suwon

26426

Research Site, Wŏnju

35365

Research Site, Daejeon

46000

Research Site, Changzhi

49241

Research Site, Busan

61469

Research Site, Gwangju

100020

Research Site, Beijing

100034

Research Site, Beijing

100037

Research Site, Beijing

100050

Research Site, Beijing

100730

Research Site, Beijing

110001

Research Site, Shenyang

110015

Research Site, Shenyang

110016

Research Site, Qingdao

200025

Research Site, Shanghai

200032

Research Site, Shanghai

200072

Research Site, Shanghai

200433

Research Site, Shanghai

201199

Research Site, Shanghai

210009

Research Site, Nanjing

210029

Research Site, Nanjing

221006

Research Site, Xuzhou

221009

Research Site, Xuzhou

225001

Research Site, Yangzhou

225300

Research Site, Taizhou

266000

Research Site, Qingdao

272029

Research Site, Jining

310003

Research Site, Hangzhou

310006

Research Site, Hangzhou

310009

Research Site, Hangzhou

310014

Research Site, Hangzhou

323000

Research Site, Lishui

330006

Research Site, Nanchang

341000

Research Site, Ganzhou

400038

Research Site, Chongqing

404000

Research Site, Wanzhou

410004

Research Site, Changsha

410015

Research Site, Changsha

411100

Research Site, Xiangtan

430030

Research Site, Wuhan

453002

Research Site, Xinxiang

510080

Research Site, Guangzhou

510120

Research Site, Guangzhou

510150

Research Site, Guangzhou

510180

Research Site, Guangzhou

519099

Research Site, Zhuhai

524001

Research Site, Zhanjiang

528000

Research Site, Foshan

550004

Research Site, Guiyang

563100

Research Site, Zunyi

570311

Research Site, Haikou

610041

Research Site, Chengdu

611130

Research Site, Chengdu

641000

Research Site, Neijiang

650032

Research Site, Kunming

650051

Research Site, Kunming

750001

Research Site, Yinchuan

750004

Research Site, Yinchuan

2100008

Research Site, Nanjing

010017

Research Site, Hohhot

030001

Research Site, Taiyuan

330-715

Research Site, Cheonan

03181

Research Site, Seoul

03312

Research Site, Seoul

03722

Research Site, Seoul

04763

Research Site, Seoul

05505

Research Site, Seoul

08308

Research Site, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY